百特醫療 (BAX) 2015 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's third-quarter 2015 earnings conference call.

    各位女士、先生,早安,歡迎參加百特國際(Baxter International)2015 年第三季財報電話會議。

  • (Operator Instructions)

    (接線員指示)

  • As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    提醒各位,本次電話會議由百特錄音,並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請於此時中斷連線。

  • I would now like to turn the call over to Miss Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話會議交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • - VP of IR

    - VP of IR

  • Thanks, Stephanie. Good morning and welcome to our third quarter 2015 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International; Jay Saccaro, Chief Financial Officer; and Scott Bohaboy, Corporate Vice President Investor Relations and Treasurer.

    謝謝你,Stephanie。早安,歡迎參加我們 2015 年第三季財報電話會議。今天與我一同出席的有:百特國際執行長暨董事長 Bob Parkinson;財務長 Jay Saccaro;以及企業副總裁(投資人關係與財務長)Scott Bohaboy。

  • On the call this morning we will be discussing Baxter's third quarter financial results and outlook for the remainder of 2015 before taking your questions. Before we review our financial performance in the quarter, I'd like to mention that this morning we issued an 8K detailing the 2014 and 2015 quarterly income statements for Baxter on a standalone, non-GAAP basis. Today's review of the results for the third quarter of 2015 and outlook for the remainder of the year will reflect comparisons to the 2014 ongoing baseline detailed in the 8K filing.

    今天上午的電話會議中,我們將在回答各位提問之前,先討論百特第三季財務結果,以及 2015 年剩餘期間的展望。在回顧本季財務表現之前,我想先提到,我們今天上午已發布一份 8-K,說明百特以獨立公司口徑、非 GAAP 基礎編製的 2014 與 2015 各季損益表。今天對 2015 年第三季結果與今年剩餘期間展望的回顧,將反映與該 8-K 申報文件中所詳述之 2014 年持續營運基準的比較。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product developments and regulatory matters contain forward-looking statements that involve risks and uncertainties and, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,我先以提醒各位作為我們事先準備發言的開場:本簡報(包括關於我們財務展望、新產品開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性;當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿與我們向 SEC 提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比較之 GAAP 財務衡量指標的調節表,已包含於我們今早發布的財報新聞稿中,並可於我們網站取得。

  • Now I'd like to turn the call over to Bob Parkinson. Bob?

    現在我想把電話會議交給 Bob Parkinson。Bob?

  • - CEO and Chairman

    - CEO and Chairman

  • Thank you, Clare. Good morning, and thanks to all of you for joining us. We're very pleased to report strong performance for the third quarter, our first as a standalone leading medical products company. These results clearly demonstrate the momentum our organization has established following the spinoff of Baxalta, momentum upon which we will build to further accelerate profitable growth in the quarters in the years ahead.

    謝謝你,Clare。早安,也感謝各位參與。我們很高興報告第三季表現強勁,這也是我們作為獨立、領先的醫療產品公司後的第一個季度。這些結果清楚展現了我們在分拆 Baxalta 之後所建立的動能;我們將在此基礎上持續推進,於未來數季與未來幾年進一步加速獲利成長。

  • As you saw in our press release this morning, for the third quarter Baxter delivered adjusted earnings of $0.41 per diluted share, significantly exceeding our guidance of $0.29 to $0.31 per diluted share. On a constant currency basis, worldwide sales increased 2% and also exceeded our guidance. After adjusting for foreign exchange and the impact of increased US competition for cyclophosphamide, sales advanced 3%.

    如各位今早在新聞稿中所見,百特第三季調整後每股稀釋盈餘為 0.41 美元,顯著高於我們先前提供的每股稀釋盈餘 0.29 至 0.31 美元指引。以固定匯率計算,全球銷售額成長 2%,同樣超出我們的指引。在調整匯率因素以及美國市場環磷醯胺(cyclophosphamide)競爭加劇的影響後,銷售額成長 3%。

  • Results in the quarter benefited from a favorable product mix, lower operating expenses and other income resulting from foreign exchange-related gains. As you know, at our May Investor Conference, we outlined a number of initiatives focused on expanding margins and accelerating profitable growth. These measures are gaining traction as evidenced by our strong third quarter performance.

    本季結果受惠於有利的產品組合、較低的營運費用,以及因匯率相關收益所帶來的其他收入。如各位所知,在 5 月的投資人會議上,我們提出多項聚焦於擴大利潤率並加速獲利成長的計畫。這些措施正逐步發揮成效,第三季的強勁表現即為明證。

  • While these are still early days, the initial results reinforce our confidence that we're clearly on the right path to achieve our financial objectives which will create value for our shareholders, patients, employees and other stakeholders. As we've repeatedly stated, our aspiration remains to exceed the profitability targets that we had laid out at that Investor Conference.

    雖然目前仍屬初期階段,但初步成果強化了我們的信心:我們顯然正走在正確的道路上,以達成財務目標,並為股東、病患、員工及其他利害關係人創造價值。正如我們一再強調,我們的目標仍是超越在該投資人會議上所提出的獲利目標。

  • As you'll recall, we're executing a three-pronged strategy to accelerate profitable growth focused on rebasing our cost structure, optimizing our existing products and services through rigorous portfolio management and, finally, expanding our offering of high-valued, differentiated products through execution of our robust new product pipeline. I want to share a few highlights from the quarter in each of these areas to demonstrate the substantive progress we're making on this journey.

    如各位所記得,我們正執行一項三管齊下的策略以加速獲利成長,重點包括:重塑成本結構;透過嚴謹的產品組合管理,最佳化既有產品與服務;最後,藉由落實我們強勁的新產品研發管線,擴大高價值、差異化產品的供應。我想就這三個面向分享本季幾項重點,展現我們在這段旅程中所取得的實質進展。

  • So let me start with cost structure. Back in May, we acknowledged the compelling need to rebase our structural costs to better align our expense base with the resource requirements of our new standalone enterprise. During the quarter, we took an important step in this regard, initiating a global work force reduction program, representing approximately 5% of all non-manufacturing payroll.

    先從成本結構談起。回到 5 月,我們承認有迫切需要重塑結構性成本,以使費用基礎更能符合我們新獨立企業所需的資源配置。本季我們在此方面採取了重要一步,啟動全球人力縮減計畫,約占所有非製造部門薪資人員的 5%。

  • This action is expected to generate approximately $130 million in annual savings once complete and is one of the first that we've taken to address our cost structure. As we move forward, we'll continue to evaluate our support levels to ensure they're appropriate. In addition, post-separation, we've implemented an array of expense controls targeting discretionary spending categories that will reduce our ongoing spend moving forward.

    此項行動預期在完成後可帶來約 1.30 億美元的年度節省,亦是我們為改善成本結構所採取的首批措施之一。展望未來,我們將持續評估支援人力與資源配置水準,以確保其適切。此外,在分拆後,我們已實施一系列費用控管措施,針對可裁量支出類別,將在未來降低我們的持續性支出。

  • Collectively, these actions will ensure that we enter 2016 with a leaner cost base that supports our new business profile and financial goals. And I can assure you that our aggressive focus in this area will continue in the months to come as we pursue additional opportunities to increase efficiency and reduce structural costs.

    綜合而言,這些行動將確保我們在 2016 年以更精實的成本基礎起步,以支撐新的業務樣貌與財務目標。我也可以向各位保證,未來幾個月我們在此領域的積極聚焦將持續,因為我們將尋求更多機會提升效率並降低結構性成本。

  • The second area that we emphasized in May was successfully managing and optimizing our existing product portfolio to improve operating performance. And as we've previously mentioned, we're taking a very disciplined approach with respect to our top-line growth opportunities to ensure that they're aligned with our margin improvement objectives and deliver appropriate returns. This year there have been certain international tenders that we have opted not to pursue, because they would not deliver benefits aligned with our profit-improvement goals.

    我們在 5 月強調的第二個面向,是成功管理並最佳化既有產品組合,以改善營運表現。如我們先前提到,對於營收成長機會,我們採取非常嚴謹的作法,以確保其與我們的利潤率改善目標一致,並帶來適當的報酬。今年有部分國際標案我們選擇不參與,因為其無法帶來符合我們獲利改善目標的效益。

  • More broadly, we're applying this same discipline to each of the product areas and geographies we serve and will evaluate our presence in select markets to ensure it's aligned with our targeted return profile. And going forward, you can expect regular updates on the progress being made in this important area.

    更廣泛而言,我們也將同樣的紀律運用於所服務的各產品領域與各地區,並將評估在部分市場的布局,以確保其符合我們目標報酬輪廓。未來,各位可期待我們就此重要領域的進展提供定期更新。

  • We know emerging market performance has been a key topic of discussion for investors. These geographies play an important role in our growth strategy, and while we're certainly not immune to the macro challenges in play, we're confident that the medically-essential nature of our products, combined with the breadth of our portfolio, will continue to position Baxter well over the long term despite some near-term volatility. During the quarter, the Company's emerging market sales rose mid-single digits on a constant currency basis, largely aligned with the long-term guidance that we provided in May.

    我們知道,新興市場表現一直是投資人討論的重點。這些地區在我們的成長策略中扮演重要角色;雖然我們當然無法完全免於宏觀環境挑戰的影響,但我們相信,產品在醫療上不可或缺的特性,加上產品組合的廣度,將使百特在面對短期波動之際,長期仍能維持良好定位。本季公司新興市場銷售額以固定匯率計算呈現中個位數成長,整體大致符合我們在 5 月提供的長期指引。

  • And finally I want to highlight some key developments in our new product pipeline. Innovation has and will always remain a cornerstone of our success and we're committed to a future of ongoing advances in areas of clear medical need. Looking out over the months and years ahead, we'll launch a number of highly-advanced new products, make significant life cycle improvements to existing offerings, and expand penetration of our current products into new geographies.

    最後,我想強調我們新產品研發管線的一些關鍵進展。創新一直是、也將永遠是我們成功的基石;我們致力於在明確的醫療需求領域持續推進未來的進步。展望未來數月與數年,我們將推出多項高度先進的新產品,對既有產品進行重要的生命週期改良,並將現有產品拓展至新的地理市場以提升滲透率。

  • Some of our recent achievements include FDA clearance for AMIA, our new automated peritoneal dialysis system with SHARESOURCE, our two-way, web-based, remote connectivity platform for home patients. AMIA is the only system approved in the US that incorporates innovative, patient-centric features such as voice guidance, a touchscreen control panel and SHARESOURCE. SHARESOURCE provides physicians with the ability to remotely access their home patient's historical treatment data and deliver individual treatment settings. We're initiating the launch of AMIA with SHARESOURCE and anticipate having units in the market before yearend.

    我們近期的成果包括:FDA 核准 AMIA——我們新的自動化腹膜透析系統,並搭載 SHARESOURCE;SHARESOURCE 是一個雙向、以網路為基礎的居家病患遠端連線平台。AMIA 是美國唯一獲核准、整合語音引導、觸控式控制面板與 SHARESOURCE 等以病患為中心創新功能的系統。SHARESOURCE 讓醫師能遠端存取其居家病患的歷史治療資料,並提供個別化的治療設定。我們正啟動 AMIA 搭載 SHARESOURCE 的上市推廣,並預期在年底前將設備投入市場。

  • Also the recently CE-marked HOMECHOICE CLARIA APD system is successfully launching in markets across Europe. CLARIA builds on the strength of our market-leading HOMECHOICE cycler, now incorporating advanced technology and the benefits of the SHARESOURCE web-based remote connectivity, among other patient and provider centric enhancements.

    此外,近期取得 CE 認證的 HOMECHOICE CLARIA APD 系統也正成功在歐洲各地市場上市。CLARIA 以我們市場領先的 HOMECHOICE 自動腹膜透析(cycler)為基礎,現已納入先進技術,以及 SHARESOURCE 網路式遠端連線的優勢,並包含其他以病患與醫療服務提供者為中心的多項強化。

  • Moving to our Hospital Products business, we continue to successfully expand the launch of our next generation SIGMA Spectrum Infusion Pump across the US, Canada and Puerto Rico. Demand for the newly-enhanced spectrum technology remains strong and is trending better than our prelaunch expectations.

    轉到我們的醫院產品事業,我們持續成功擴大在美國、加拿大與波多黎各推出新一代 SIGMA Spectrum 輸注幫浦。對於新強化的 Spectrum 技術之需求仍然強勁,且趨勢優於我們上市前的預期。

  • Also in the third quarter, Hospital Products announced FDA approval of Cefazolin 2-gram injection in our proprietary galaxy container. Cefazolin has been on the FDA's drug shortage list and in a variety of presentations due to high demand. This is the first of nine molecules that Baxter is developing and expects to launch over the next several years and we recently submitted the second molecule for review with the FDA and expect to launch this molecule early in 2016. As these highlights demonstrate, we're making meaningful advances across our overall margin improvement framework and this is only the start.

    同樣在第三季,醫院產品事業宣布我們專有的 Galaxy 容器之 Cefazolin 2 克注射劑獲得 FDA 核准。由於需求旺盛,Cefazolin 已被列入 FDA 藥品短缺清單,且短缺涵蓋多種劑型/包裝。這是 Baxter 正在開發、並預期於未來數年推出的九個分子中的第一個;我們近期也已將第二個分子送交 FDA 審查,並預期於 2016 年初推出該分子。如同這些重點所示,我們正於整體毛利改善架構上取得具意義的進展,而這僅僅是開始。

  • So with that, let me now turn it over to Jay for a closer look at the third quarter performance and also outlook for the remainder of the year, and then prior to taking your questions, I'd like to take a moment to make some closing comments. So, Jay, please.

    那麼,接下來我把時間交給 Jay,請他更深入說明第三季表現,以及今年剩餘期間的展望;在回答各位問題之前,我也想花一點時間做一些結語。那麼,Jay,請。

  • - CFO

    - CFO

  • Thanks, Bob. Good morning, everyone. As Bob mentioned, adjusted earnings in the second quarter of $0.41 per diluted share exceeded our previously issued guidance range of $0.29 to $0.31 per share. Performance in the quarter benefited from the disciplined management of discretionary expenses, a favorable product mix, which included better- than-expected cyclophosphamide sales and other income from foreign exchange-related gains.

    謝謝你,Bob。各位早安。如 Bob 所提到,第二季調整後每股稀釋盈餘為 0.41 美元,超出我們先前發布的每股 0.29 至 0.31 美元指引區間。本季表現受惠於對可自由裁量費用的嚴謹管理、有利的產品組合(其中包含高於預期的 cyclophosphamide 銷售),以及來自外匯相關收益的其他收入。

  • On a GAAP basis, income from continuing operations of $2 million included net after tax special items totaling $223 million or $0.41 per diluted share, primarily for costs associated with the Company's spinoff of Baxalta, business optimization initiatives, debt extinguishment and intangible asset amortization.

    以 GAAP 基礎計,持續營運業務所得為 200 萬美元,其中包含稅後特殊項目淨額合計 2.23 億美元(或每股稀釋 0.41 美元),主要為與公司分拆 Baxalta、業務最佳化計畫、債務清償以及無形資產攤銷相關的成本。

  • Before I walk you through the P&L, I wanted to take a moment to make some comments regarding our historical financial statements which we detailed this morning in our 8K filing. First, I want to start by acknowledging your patience with respect to these statements. Given the highly integrated nature of the bioscience and medical products businesses' pre-spend, the preparation of the historical filings required significant time.

    在我帶各位逐項檢視損益表之前,我想先就我們今早於 8-K 申報中詳述的歷史財務報表做一些說明。首先,我要先感謝各位對這些報表的耐心等待。由於生物科學與醫療產品業務在分拆前高度整合,編製歷史申報文件需要相當多時間。

  • Second, I wanted to highlight that these statements have inherent complexities associated with them when comparing current results with those of prior periods. More specifically, for the most part, prior periods do not reflect income we received from Baxalta related to transition service agreements and deferred country closings. In addition, given the highly integrated nature of our businesses, we were not able to clearly isolate select expense categories between Baxalta and Baxter in the discontinued operations presentation.

    第二,我想強調,將目前結果與先前期間相比時,這些報表本身存在一些固有的複雜性。更具體而言,多數情況下,先前期間並未反映我們自 Baxalta 因過渡服務協議與遞延的國家結束作業所取得的收入。此外,鑑於我們業務高度整合,在停業部門表達中,我們無法在 Baxalta 與 Baxter 之間清楚區分部分費用類別。

  • And lastly, the historical P&Ls included payroll expenses for certain positions initially determined as backfills for employees that transitioned to Baxalta. Upon further evaluation post-spend, some of these roles have since been eliminated and will not be replaced. Investors should consider all of these factors when comparing Baxter's current results to historical periods.

    最後,歷史損益表包含某些職位的薪資費用,這些職位最初被認定為替補轉任至 Baxalta 的員工之人力補缺。在分拆後進一步評估後,其中部分職務已被取消,且不會再補人。投資人於比較 Baxter 目前結果與歷史期間時,應將上述因素一併納入考量。

  • Now, let me briefly walk you through the P&L by line item before turning to the financial outlook for the fourth quarter of 2015. Starting with sales, worldwide revenues of approximately $2.5 billion declined 8% on a reported basis. On a constant currency basis, sales increased 2%, which compares favorably to our guidance for the quarter of comparable sales for the prior year.

    現在,在轉到 2015 年第四季財務展望之前,我先按損益表項目簡要帶各位看一遍。先從營收開始,全球營收約 25 億美元,以報表基礎計下滑 8%。以固定匯率計,銷售成長 2%,與我們對本季「與前一年可比銷售」的指引相比表現更佳。

  • Excluding the impact of both currency and increased competition for cyclophosphamide, Baxter's sales grew 3% globally. Sales in the US declined 1% on a reported basis and after adjusting for cyclophosphamide, US sales advanced 3%. International sales, on a constant currency basis, increased 3% and declined 12% on a reported basis.

    若排除匯率以及 cyclophosphamide 競爭加劇的影響,Baxter 全球銷售成長 3%。美國銷售以報表基礎計下滑 1%,若調整 cyclophosphamide 影響,美國銷售成長 3%。國際銷售以固定匯率計成長 3%,但以報表基礎計下滑 12%。

  • In terms of individual business performance within Hospital Products, global sales of approximately $1.5 billion declined 7% and on a constant currency basis sales rose 2%. Adjusting for the impact of US cyclophosphamide in foreign exchange, Hospital Product sales increased 4%.

    就醫院產品內各業務的個別表現而言,全球銷售約 15 億美元,下滑 7%;以固定匯率計,銷售上升 2%。若調整美國 cyclophosphamide 與外匯的影響,醫院產品銷售成長 4%。

  • Within the Fluid Systems franchise, sales of $526 million declined 3% and, on a constant currency basis, sales advanced 5%. Performance in the quarter was driven by double-digit growth in the Infusion Systems business, supported by the successful launch of our Next-Generation SIGMA SPECTRUM pump, as well as a favorable customer mix for US IV solutions.

    在輸液系統(Fluid Systems)事業群中,銷售為 5.26 億美元,下滑 3%;以固定匯率計,銷售成長 5%。本季表現主要由輸注系統(Infusion Systems)業務的兩位數成長所帶動,受惠於我們新一代 SIGMA SPECTRUM 幫浦的成功上市,以及美國靜脈輸液(IV)解決方案較有利的客戶組合。

  • Sales in the Integrated Pharmacy Solutions, or IPS, franchise totaled $590 million and declined 8%. On a constant currency basis, sales grew 1%. Excluding cyclophosphamide impact, sales in the category increased 9% driven by strength across the franchise, which includes our nutritional products, pharmacy injectables, and hospital pharmacy compounding services. IPS performance in the quarter also benefited from a US government order for the pharmacy injectable ProtoPAM.

    整合藥局解決方案(Integrated Pharmacy Solutions,IPS)事業群銷售合計 5.90 億美元,下滑 8%。以固定匯率計,銷售成長 1%。若排除 cyclophosphamide 影響,該類別銷售成長 9%,動能來自整個事業群的強勁表現,包括我們的營養產品、藥局注射劑,以及醫院藥局調配服務。IPS 本季表現亦受惠於美國政府對藥局注射劑 ProtoPAM 的訂單。

  • During the third quarter, US cyclophosphamide sales totaled $80 million as compared to our previous expectation of approximately $50 million. To date, there remains one competitor in the US market, but we continue to expect additional competition to enter, although the timing of these entrants remains uncertain.

    第三季期間,美國 cyclophosphamide 銷售合計 8,000 萬美元,高於我們先前約 5,000 萬美元的預期。截至目前,美國市場仍有一家競爭對手,但我們仍預期會有更多競爭者進入,惟其進入時點仍不確定。

  • Revenues in surgical care, which includes our anesthesia and biosurgery products, were $322 million in the quarter and declined 5%. On a constant currency basis, sales grew 2%, driven by strong performance globally in the anesthesia business and growth of core surgical sealants and hemostasis products, including our market-leading FloSeal hemostatic matrix.

    外科照護(surgical care)業務(包含麻醉與生物外科產品)本季營收為 3.22 億美元,下滑 5%。以固定匯率計,銷售成長 2%,主要由麻醉業務在全球的強勁表現,以及核心外科封合劑與止血產品的成長所帶動,其中包括我們市場領先的 FloSeal 止血基質。

  • This performance was offset by lower sales of select non-core biosurgery products, including Peri-Strips, where prior years' sales benefited from a competitor being out of the market who has since returned.

    上述表現部分被部分非核心生物外科產品銷售下滑所抵銷,包括 Peri-Strips;先前年度該產品銷售受惠於一名競爭對手退出市場,而該競爭對手目前已回歸。

  • Finally sales in the BioPharma Solutions and other category, which is our pharma partnering business, totaled $106 million and, as expected, declined 19% on a reported basis or 12% on a constant currency basis. As we have previously discussed, this decline is driven by a large customer choosing to self-manufacture products that were previously contract manufactured by Baxter. I would also note that this category now reflects sales for products Baxter is manufacturing on behalf of Baxalta, which totaled approximately $14 million in the quarter.

    最後,BioPharma Solutions 與其他類別(即我們的製藥合作夥伴業務)銷售合計 1.06 億美元,如預期以報表基礎計下滑 19%,或以固定匯率計下滑 12%。如我們先前所討論,這一下滑係因一位大型客戶選擇自行生產先前由 Baxter 代工生產的產品。我也要指出,該類別目前亦反映 Baxter 代表 Baxalta 製造之產品銷售,本季約為 1,400 萬美元。

  • Turning to the Renal business, global Renal sales totaled $943 million, reflecting a decline of 11% on a reported basis. Excluding the impact of foreign currency, sales grew 1%. Performance in the quarter was driven by mid-single-digit growth in our peritoneal dialysis business and high single-digit growth in the acute business. This growth was offset by lower sales in our chronic hemodialysis business, resulting from our previously-discussed decisions to forego certain lower-margin sales opportunities, the implementation of select austerity measures in western Europe and a particularly competitive environment for dialyzers.

    接著看腎臟(Renal)業務,全球腎臟業務銷售合計 9.43 億美元,以報表基礎計下滑 11%。若排除外幣影響,銷售成長 1%。本季表現主要由腹膜透析業務的中個位數成長,以及急性(acute)業務的高個位數成長所帶動。上述成長被慢性血液透析業務銷售下滑所抵銷,該下滑源於我們先前已討論的決策:放棄部分較低毛利的銷售機會、西歐實施部分撙節措施,以及透析器市場競爭特別激烈。

  • Turning to the rest of the P&L, gross margin in the quarter was 43.8% and compared favorably to our expectations, driven primarily by positive product mix in the quarter. SG&A totaled $670 million and decreased 15% on a reported basis. On a constant currency basis, SG&A declined 6%, reflecting the benefit of the initial actions we have taken to rebase our cost structure and reduce discretionary expenses along with transition service income we received from Baxalta in the quarter.

    接著看損益表其餘部分,本季毛利率為43.8%,優於我們的預期,主要受惠於本季正向的產品組合。銷售、一般及行政費用(SG&A)合計6.70億美元,以報告基礎計算下降15%。以固定匯率基礎計算,SG&A下降6%,反映我們已採取的初步行動所帶來的效益,包括重置成本結構、降低可自由支配費用,以及本季自Baxalta取得的過渡服務收入。

  • Further actions to optimize our support structure needs are somewhat constrained in the short term by the transition service agreements we have in place with Baxalta. These agreements extend over the next 18 to 24 months, and as we pursue additional opportunities to streamline our ongoing functional support requirements, we must be mindful of the services we're providing to Baxalta.

    為了最佳化我們支援架構需求而採取的進一步行動,在短期內會受到我們與Baxalta之間既有的過渡服務協議所限制。這些協議將延續未來18至24個月;當我們尋求更多機會精簡持續性的職能支援需求時,必須留意我們正在提供給Baxalta的服務。

  • R&D spending in the quarter of $140 million decreased 5% versus the prior year. On a constant currency basis, R&D expenditures increased 2% as we have balanced increased investments to support our new product pipeline with efforts to optimize our overall R&D spend. Operating margin in the quarter was 11.2%, which compared favorably to our guidance of 9% for the second half of 2015, driven by the positive gross margin and operating expense savings I just referenced.

    本季研發(R&D)支出為1.40億美元,較去年同期下降5%。以固定匯率基礎計算,研發支出增加2%,因為我們在加大投資以支持新產品研發管線的同時,也致力於最佳化整體研發支出。本季營業利益率為11.2%,優於我們對2015年下半年9%的指引,主要受惠於前述較佳的毛利率與營業費用節省。

  • As Bob mentioned, this quarter we implemented a global work force reduction program which will generate approximately $130 million in annual savings when fully implemented. This program is a component of our comprehensive strategy to improve profitability and significantly expand operating margins by 2020. As we move forward, we'll continue to streamline our operations and control spending in support of this objective.

    如Bob所提到的,我們本季實施了全球人力精簡計畫,全面落實後預計每年可節省約1.30億美元。此計畫是我們提升獲利能力、並在2020年前大幅擴大營業利益率之整體策略的一部分。展望未來,我們將持續精簡營運並控管支出,以支持此目標。

  • All of our cost structure initiatives remain on track and we are confident in our ability to achieve the 2020 operating margin target. Interest expense was $34 million in the third quarter compared to $31 million last year. During the quarter, we successfully executed a tender for $2.7 billion of outstanding bonds. The benefit of this reduced debt level was more than offset by lower levels of capitalized interest in the quarter.

    我們所有成本結構相關的措施皆按計畫推進,我們對達成2020年營業利益率目標充滿信心。第三季利息費用為3,400萬美元,去年同期為3,100萬美元。本季我們成功完成對27億美元未償還債券的要約收購(tender)。本季因債務水位降低所帶來的效益,已被資本化利息水準下降所帶來的影響所抵銷且有餘。

  • At quarter end, our current gross outstanding debt balance was approximately $6.7 billion, and consisted of approximately $4.8 billion of bonds and other term debt, approximately $1.5 billion of outstanding balances on our revolving bank line, and approximately $400 million of commercial paper. As previously communicated, we'll look to further delever our balance sheet in the months ahead as part of our strategy to optimize the retained equity state.

    截至季末,我們目前的未償還總債務餘額約為67億美元,其中約48億美元為債券及其他定期債務,約15億美元為循環銀行授信項下的未償餘額,約4億美元為商業本票。如先前所溝通,我們將在未來數月進一步降低槓桿,作為最佳化保留股權狀態策略的一部分。

  • In addition to these activities, we expect our routine stake utilization plans to include equity-for-equity exchanges, as well as a contribution to our US-qualified pension plan subject to regulatory approval. Cash on hand at the end of the quarter totaled approximately $2 billion. Other income totaled $39 million and included a planned gain related to the sale of select equity investments of approximately $20 million and an unplanned foreign exchange gain from hedges on balance sheet positions of approximately $20 million.

    除上述活動外,我們預期例行的持股運用計畫將包括以股換股的交換,以及在取得監管核准後,對我們的美國合格退休金計畫進行提撥。季末手上現金合計約20億美元。其他收益合計3,900萬美元,其中包括出售部分股權投資所帶來的既定收益約2,000萬美元,以及針對資產負債表部位避險所產生的非預期外匯收益約2,000萬美元。

  • The tax rate was 20.8% for the quarter. And as previously mentioned, adjusted earnings of $0.41 per diluted share exceeded our guidance range of $0.29 to $0.31.

    本季稅率為20.8%。如先前所提,調整後每股稀釋盈餘0.41美元,高於我們0.29至0.31美元的指引區間。

  • Let me conclude my comments this morning by providing an update on our full-year sales guidance and outlook for the fourth quarter. Starting with sales on a constant currency basis, we now expect sales for the full year 2015 to increase approximately 1%. And after adjusting both periods for the cyclophosphamide impact, we continue to expect underlying growth of approximately 3%. This is driven by growth in the Hospital Products business of approximately 1% or 4% excluding cyclophosphamide.

    最後,我在今天上午的發言將以更新全年銷售指引與第四季展望作結。先從固定匯率基礎的銷售來看,我們目前預期2015年全年銷售將成長約1%。在將兩個期間皆就環磷醯胺(cyclophosphamide)的影響進行調整後,我們仍預期基本面成長約3%。此成長主要由醫院產品(Hospital Products)業務約1%的成長所帶動;若排除環磷醯胺,則約為4%。

  • Specific to the franchises within Hospital Products, we now expect sales growth of 4% to 5% for Fluid Systems, reflecting the strong performance from Infusion Systems and US IV solutions. For the Integrated Pharmacy Solutions franchise, we now expect sales to decline low single digits. As you know, this category includes cyclophosphamide.

    就醫院產品業務內各事業群而言,我們目前預期流體系統(Fluid Systems)銷售成長4%至5%,反映輸注系統(Infusion Systems)與美國靜脈輸液(US IV solutions)的強勁表現。對於整合藥事解決方案(Integrated Pharmacy Solutions)事業群,我們目前預期銷售將呈現低個位數下滑。如各位所知,該類別包含環磷醯胺。

  • For the full year 2015, we now estimate US cyclophosphamide sales to total more than $250 million, reflecting the $30 million third quarter benefit and an additional benefit of approximately $25 million in the fourth quarter relative to previous guidance. Growth for the category after adjusting for cyclophosphamide is expected to increase mid-single digits. With the Surgical Care franchise, we anticipate sales to grow approximately 3%. This growth is somewhat slower than our original expectations and reflects (inaudible) sales of non-core biosurgery products.

    就2015年全年而言,我們目前估計美國環磷醯胺銷售總額將超過2.50億美元,反映第三季3,000萬美元的挹注,以及第四季相較先前指引額外約2,500萬美元的挹注。在就環磷醯胺進行調整後,該類別的成長預期將提升至中個位數。在外科照護(Surgical Care)事業群方面,我們預期銷售將成長約3%。此成長略低於我們原先預期,並反映(聽不清)非核心生物外科產品的銷售。

  • And finally, for the Hospital Products business, we now expect the other category, which includes our BioPharma Solutions franchise to decline mid-single digits. As I mentioned earlier, this category now includes sales related to contract manufacturing agreements we have in place with Baxalta.

    最後,就醫院產品業務而言,我們目前預期其他類別(包含我們的生物製藥解決方案(BioPharma Solutions)事業群)將呈現中個位數下滑。如我先前提到,該類別目前也包含我們與Baxalta既有的委託製造協議相關銷售。

  • For the Renal business, we now expect full-year sales to increase approximately 1%, as we remain focused on maximizing the profitability of this business and maintaining a disciplined approach with respect to international tenders. In addition, as a reminder, the Renal business is more exposed to the current volatility in emerging markets than other areas of our portfolio. While over the long term we feel very confident that we're well-positioned to capitalize on the growth opportunities within these geographies, near-term performance will be impacted by softness in these markets.

    在腎臟(Renal)業務方面,我們目前預期全年銷售將成長約1%,因我們仍專注於最大化該業務的獲利能力,並在國際標案方面維持紀律性的作法。此外提醒各位,腎臟業務相較於我們投資組合中的其他領域,更容易受到新興市場當前波動的影響。雖然長期而言我們非常有信心已具備良好定位,可把握這些地區的成長機會,但短期表現將受到這些市場疲弱的影響。

  • Moving to the fourth quarter of 2015, we expect sales growth, excluding the impact of foreign currency, to decline approximately 1% and after adjusting for US cyclophosphamide, to increase 1% to 2%. At current foreign exchange rates, we expect reported sales to decline approximately 9%.

    接著看2015年第四季,我們預期在排除外幣影響後,銷售成長將下滑約1%;而在就美國環磷醯胺進行調整後,則預期成長1%至2%。以目前外匯匯率計算,我們預期報告銷售將下滑約9%。

  • For the fourth quarter we expect an operating margin between 9.5% and 10% which, again, compares favorably to our previously-issued second half guidance of 9%. The sequential decline from the third quarter reflects incremental operational improvements and additional savings from our cost reduction initiatives being more than offset from the impact of lower sales of higher margin products like cyclophosphamide and ProtoCAM, as well as the negative impact from foreign exchange.

    第四季我們預期營業利益率介於9.5%至10%,同樣優於我們先前發布的下半年9%指引。相較第三季的季減,反映營運改善的增量效益與成本削減措施帶來的額外節省,已被高毛利產品(如環磷醯胺與ProtoCAM)銷售下滑的影響,以及外匯的負面影響所抵銷且有餘。

  • We expect interest expense to total approximately $35 million and other to be an expense item of approximately $5 million in the quarter. We continue to expect a tax rate of approximately 20% and an average share count of 550 million shares. As stated in our press release, we expect adjusted earnings, excluding special items of $0.30 to $0.32 per diluted share. Relative to our previous guidance, earnings in the quarter reflect the benefit of incremental sales for cyclophosphamide, offset by a negative impact from foreign exchange.

    我們預期本季利息費用合計約3,500萬美元,而其他項目預期為約500萬美元的費用。我們仍預期稅率約20%,平均流通股數為5.50億股。如我們新聞稿所述,我們預期調整後盈餘(不含特殊項目)為每股稀釋盈餘0.30至0.32美元。相較先前指引,本季盈餘反映環磷醯胺增量銷售的正面效益,但被外匯的負面影響所抵銷。

  • Before we open up the call for Q&A, I'd like to turn the call back over to Bob for some closing comments. Bob?

    在我們開放問答之前,我想把電話交回給Bob,請他做一些結語。Bob?

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks, Jay. So before we do open up the Q and A, I would like to spend just a minute addressing Baxter's path forward. Certainly our biggest milestone in 2015 was the successful completion of the Bioscience spinoff, resulting in the establishment of two leading global healthcare Companies. The spinoff positioned both Baxter and Baxalta with improved focus and an ability to innovate and operate more effectively which will create enhanced value for all of our stakeholders.

    謝謝,Jay。在我們開始問答之前,我想花一分鐘談談Baxter未來的前進方向。毫無疑問,我們在2015年最大的里程碑,是成功完成生物科學(Bioscience)業務的分拆,進而成立兩家領先的全球醫療保健公司。這次分拆讓Baxter與Baxalta都能更聚焦,並提升創新與營運效率,從而為我們所有利害關係人創造更高的價值。

  • I would tell you I couldn't be more pleased with the progress the Baxter organization has made following the spinoff and my confidence in our future has never been stronger. Our third-quarter results I think demonstrate the commitment of all of our employees around the world and the clear alignment that exists throughout the organization on achieving our strategic operational and financial objectives.

    我想告訴各位,對於百特組織在分拆之後所取得的進展,我再滿意不過;而我對我們未來的信心也從未如此堅定。我認為,我們第三季的業績展現了全球所有員工的投入承諾,也清楚反映出整個組織在達成我們策略性營運與財務目標上高度一致的方向。

  • Given this momentum which has been established, I'd like to touch on the search process for a new Baxter Chief Executive. As I mentioned last quarter, this is a front burner topic for the Board. I will tell you we're making very good progress in the search for my successor. As I think you can understand, due to the confidential nature of the search, we can't comment now on timing or other specifics this morning.

    在既有的這股動能之下,我想談談尋找新任百特執行長的流程。如同我在上季提到的,這是董事會最優先處理的議題之一。我可以告訴各位,我們在尋找我的接班人方面進展非常順利。如各位所理解,基於遴選程序的保密性,我們今天早上無法就時程或其他細節發表評論。

  • Turning to capital allocation, and in particular our use of the retained Baxalta equity stake, where our primary objective remains maximizing the after-tax value of the stake, consistent with our previous statements, we intend to use the stake in a highly tax-efficient manner to optimize our capital structure which will provide additional flexibility to support organic growth initiatives and pursue external business development opportunities. Regarding M&A, while we did not include any benefit in the financial projections we provided in May, going forward, we expect M&A to be a key component of our strategy to accelerate profitable growth.

    接著談資本配置,特別是我們對所保留的 Baxalta 股權部位之運用;我們的首要目標仍是將該部位的稅後價值最大化。依照我們先前的說法,我們打算以高度稅務效率的方式運用該股權部位,以最佳化我們的資本結構,進而提供更多彈性來支持有機成長計畫並追求外部業務發展機會。至於併購(M&A),雖然我們在5月提供的財務預測中未納入任何併購效益,但展望未來,我們預期併購將成為我們加速獲利成長策略的重要組成。

  • Over the next 12 months, as we enhance our balance sheet and progress on our post-spend margin improvement initiatives, we'll have significant flexibility to evaluate opportunities that are more transformative in both scope and scale but still align with our business model and leverage our broad channel strength and geographic presence. In closing, our aspiration remains to be a truly great Company in service of our mission to save and sustain lives and I'm confident that we're on our way to achieving this goal.

    在未來12個月,隨著我們強化資產負債表並推進支出後的毛利率改善計畫,我們將具備相當大的彈性,去評估在範疇與規模上更具轉型性的機會,同時仍與我們的商業模式一致,並能運用我們廣泛的通路優勢與地理布局。最後,我們的願景仍是成為一家真正卓越的公司,致力於實現「拯救並維持生命」的使命;我有信心我們正走在達成此目標的道路上。

  • So with that, I think we can now open up the call to questions, Clare.

    那麼接下來,我想我們可以開放提問了,Clare。

  • Operator

    Operator

  • Thank you. We will now begin the question-and-answer session.

    謝謝。我們現在開始問答環節。

  • (Operator Instructions)

    (接線員指示)

  • We appreciate everyone's patience and would like to provide as many of you as possible the opportunity to ask a question. We will pause for a moment while the list is being compiled. I would like to remind participants that this call is being recorded and additional replay will be available on the Baxter international website for 30 days at www.baxter.com.

    感謝各位的耐心,我們希望盡可能讓更多人有機會提問。我們將暫停片刻以彙整提問名單。提醒各位,本次電話會議將被錄音,並可於百特國際網站 www.baxter.com 取得為期30天的重播。

  • And our first question comes from David Roman with Goldman Sachs. Your line is open.

    第一個問題來自高盛(Goldman Sachs)的 David Roman。您的線路已開通。

  • - Analyst

    - Analyst

  • Thank you. Good morning, everybody. I wanted to ask one strategic question, one financial question, and maybe, Bob, I'll pick up on where you ended the call with respect to M&A. I think at the time of the Analyst Meeting back in May, the communication was that unlikely to see M&A for at least 12-plus months. And now it sounds like M&A is becoming a more important part of the potential forward path.

    謝謝。各位早安。我想問一個策略問題、一個財務問題;另外,Bob,我想延續你在談到併購(M&A)時作結的部分。我記得在5月的分析師會議上,當時的溝通是至少在12個月以上不太可能看到併購。但現在聽起來,併購正成為未來路徑中更重要的一部分。

  • And understandably it might not happen immediately, but can you maybe talk us through the evolution of the thought process around M&A and give us some flavor for why M&A has become a -- potentially moved up the priority scheme and then what type of deals you might be considering?

    我理解可能不會立刻發生,但你能否帶我們了解一下你們對併購思考的演變,並分享一些脈絡:為什麼併購可能在優先順序上往前移?以及你們可能會考慮什麼類型的交易?

  • - CEO and Chairman

    - CEO and Chairman

  • I think a lot a lot of this, David, is about timing. At the May conference I commented on two constraints in the short term, certainly, within, let's say, the first12 months. One was some financial constraints certainly as we navigated our way through the retained stake and so on. But the second one being organizational, completing the integration of Gambro, our ability to continue to support the Baxalta spinoff, which requires a significant organizational commitment on Baxter's behalf going forward.

    David,我想這很大一部分與時點有關。在5月的會議上,我提到短期內、確切地說在前12個月左右,有兩項限制。第一是財務上的限制,特別是我們在處理保留股權部位等事項時。第二則是組織面的限制:完成 Gambro 的整合,以及我們持續支援 Baxalta 分拆;這些都需要百特在未來投入相當大的組織資源。

  • Relative to the organizational constraint, frankly, things have moved ahead even better than we had anticipated, I think, on all fronts. So I think our organizational capacity to contemplate being more proactive, perhaps maybe even a little sooner on M&A, is better today than what maybe we had anticipated in May. And it's not going to be long before we work through this retained state, and so on. And as I commented in my prepared comments, we're going to have significant flexibility.

    就組織面的限制而言,坦白說,各方面的進展都比我們原先預期更好。因此,我認為我們在組織能力上,去思考更積極、也許在併購上更早一些採取行動的條件,比5月時我們預期的更成熟。而且距離我們處理完這個保留股權部位等事項,也不會太久。正如我在事先準備的發言中提到的,我們將擁有相當大的彈性。

  • So we have advanced our thinking on things that we might want to do on the M&A front. I'm not going to be real specific in terms of size, but possibly we could be thinking bigger than maybe what we've characterized in the past.

    因此,我們已經推進了對併購面向可能採取行動的思考。我不會在規模上講得很具體,但我們可能會考慮比過去所描述的更大型一些。

  • What we do know is we have such a strong presence in the acute care hospital channel. Wherever you go in the world, the Baxter brand is well-recognized, it's respected, and so the opportunity to do some things that fill out that channel more effectively we're very interested in. So beyond that, I'm not going to be any more specific than that, but hopefully that gives you maybe a little bit more color as to how our thinking's evolved since we got together last May.

    我們確定的是,我們在急性照護醫院通路擁有非常強的布局。在世界各地,百特品牌都廣為人知且備受尊重,因此,我們對於能更有效補強該通路的機會非常有興趣。除此之外,我就不再更具體了,但希望這能讓你更了解自去年5月我們見面以來,我們的思考如何演變。

  • - Analyst

    - Analyst

  • That's definitely helpful. Thank you. And then just on the financial side, obviously the second half of 2015 is coming in better than you had communicated, some of which is tied to a slower rundown in cyclophosphamide than might have been previously expected, but how should we think about what we're seeing in the back half of 2015 as it relates to the initial targets you provided for 2016 back in May? How much of what we're seeing is sustainable versus more one-time in nature?

    這確實很有幫助。謝謝。接著就財務面來看,顯然2015年下半年表現優於你們先前的溝通,其中一部分與 cyclophosphamide 的下滑速度比先前預期更慢有關;但我們應該如何看待2015年下半年所呈現的狀況,與你們在5月提出的2016年初始目標之間的關聯?我們看到的改善有多少是可持續的,又有多少較偏一次性因素?

  • - CEO and Chairman

    - CEO and Chairman

  • Jay, you want to handle that?

    Jay,你要回答這題嗎?

  • - CFO

    - CFO

  • Sure. Just making comments in terms of third quarter performance, we over achieved the mid point of our guidance by $0.11 and there were really three primary drivers which contributed to that. One was cyclophosphamide; a second item related to some other income driven by foreign exchange and the timing of investment gains; and then the third piece relates to savings related to the cancellation of [OPE visions] spending controls that we put in place as well.

    好的。就第三季表現來做說明,我們比指引中點高出0.11美元;主要有三個驅動因素促成這個超預期表現。第一是 cyclophosphamide;第二項是與外匯及投資收益認列時點相關所帶來的其他收入;第三則是與我們所採取的支出控管相關的節省,包含取消 [OPE visions] 的支出控管所帶來的節省。

  • So those really are the three primary drivers of the over achievement in Q3. As we move forward, what I would say is the one that was most important to us was the operational performance related to the spending controls that we put in place. And we're not updating 2016 guidance at this stage, but what I will tell you is we are very confident in our ability to execute, particularly on the cost side and also on the margin side as we move forward. We'll update guidance in January, but at this stage I think this first quarter was a very important building block for us to put in place that gives us a high level of confidence as we move forward through the rest of the plan.

    以上就是第三季超預期的三個主要驅動因素。展望未來,我想說對我們最重要的是與我們所採取的支出控管相關的營運表現。我們現階段不更新2016年的指引,但我可以告訴各位,我們對於執行能力非常有信心,特別是在成本端,以及未來推進毛利率表現方面。我們會在1月更新指引;但就目前而言,我認為這第一季(此處指第三季)是非常重要的基礎建設,讓我們在推進其餘計畫時具備高度信心。

  • - Analyst

    - Analyst

  • Okay. Got it. Thank you very much.

    好的。了解。非常謝謝。

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks, David.

    謝謝你,David。

  • Operator

    Operator

  • Our next question comes from Matt Taylor with Barclays. Your line is open.

    下一個問題來自 Barclays 的 Matt Taylor。您的線路已開通。

  • - Analyst

    - Analyst

  • Hi. Thanks for taking the question. So you had good performance, you outlined the three factors. I guess could you expound a little bit on the third one that you talked about in terms of the savings cancellation? And I was just wondering if you could help us put that into context with your prior guidance? How much of the outside was driven by that, and then how much does that change your margin expectations, maybe relative to the LRP? What [wasn't] in the guidance before?

    嗨。謝謝讓我提問。你們表現不錯,也列出了三個因素。我想請你們再多談一點第三項,也就是你提到的「取消」所帶來的節省,能否再詳細說明?另外也想請你們協助我們把這點放回你們先前指引的脈絡中理解:超出預期的部分有多少是由此驅動?以及這會如何改變你們對毛利率的預期,可能相對於長期規劃(LRP)而言?先前的指引中有哪些並未納入?

  • - CFO

    - CFO

  • Yes. I think the biggest factor was really the timing of the action. So as we think about the performance in Q3, we had approximately $25 million, maybe a little bit more than that, of savings related to two areas, discretionary spending controls that we put in place and then also the cancellation of open rolls.

    是的。我認為最大的因素其實是行動的時點。因此,當我們回顧第三季的表現時,我們約有2,500萬美元、可能略高一些的節省,主要來自兩個面向:我們所實施的非必要(可裁量)支出管控,以及取消未完成的open rolls。

  • And so as we had a high level of confidence that we were going to successfully execute the spin and we started to see the performance work out well very early in the July time frame, we were very proactive in terms of pulling forward some of the spending initiatives that we had earmarked for later in the year.

    因此,當我們對成功完成分拆(spin)有很高的信心,並且在7月初期就很早看到績效表現良好時,我們在把原本規劃於年底較晚才推動的一些支出計畫提前方面,採取了非常積極的作法。

  • So some of the benefit that we saw in Q3 is not something that we would, quote, unquote, tack on to future periods, but, rather, something that benefits Q3 specifically. And because we were confident in our ability to execute, we were able to put those pieces in place earlier than we previously expected. So as far as the impact on the long-range plan, I wouldn't say that this is, quote, unquote, incremental at this stage, but, rather, it just gives us confidence that we're going to be able to execute as we move forward.

    所以,我們在第三季看到的部分效益,並不是我們會(所謂)加到未來期間的東西;相反地,它是特別有利於第三季的項目。而且因為我們對執行能力有信心,我們得以比先前預期更早把這些措施到位。因此,就對長期計畫的影響而言,我不會說在這個階段這是(所謂)額外增量,而是它讓我們更有信心,隨著我們往前推進,將能夠如期執行。

  • - Analyst

    - Analyst

  • Okay. That's helpful. And then I guess another piece you've talked a little bit about that wasn't in the planned numbers is an opportunity on price, maybe in the PD business or in the IV Solutions business. Can you talk a little bit about the opportunities in each of those two businesses, and I guess why you feel like pricing may be a lever that you can pull over the next 12 months?

    好的。這很有幫助。接著我想,另一個你們稍微提到、但不在原先規劃數字中的部分,是價格方面的機會,可能在PD業務或IV Solutions業務。你能否談談這兩個業務各自的機會,以及你為什麼覺得在未來12個月,定價可能是一個你們可以運用的槓桿?

  • - CEO and Chairman

    - CEO and Chairman

  • Matt, I don't think there's anything new there from what we've messaged previously on that, and so for a number of reasons, including [competitive] reasons, I don't think I want to expand on that any further this morning.

    Matt,我不認為那裡有任何不同於我們先前對外傳達的內容;基於多項原因(包括[競爭]因素),我想我今天早上不會再進一步延伸說明。

  • - Analyst

    - Analyst

  • All right. Thanks a lot for the comment.

    好的。非常感謝你的回覆。

  • - CFO

    - CFO

  • Thanks, Matt.

    謝謝你,Matt。

  • Operator

    Operator

  • Our next question comes from Bob Hopkins with Bank of America Merrill Lynch. Your line is open.

    下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的Bob Hopkins。您的線路已開通。

  • - Analyst

    - Analyst

  • Hi, thanks. Can you hear me okay?

    嗨,謝謝。你們聽得到我嗎?

  • - CEO and Chairman

    - CEO and Chairman

  • Sure, Bob, go ahead.

    當然可以,Bob,請說。

  • - Analyst

    - Analyst

  • Great. So I wanted to follow up with a couple questions on operating margins. So I'll just rattle off a few things here. So in the quarter, how much of the roughly 200 basis points of operating margin beat was due to the $30 million in better cyclo sales? And in terms of the fourth quarter guidance which looks like it's down by about 150 basis points, could you just break that out a little bit more, because it seems cyclo is only coming down by $5 million, so I just want to understand the Q3 to Q4 dynamic there a little bit in a little bit more detail.

    很好。我想就營業利益率追問幾個問題。我先快速列幾點。本季大約200個基點的營業利益率優於預期,其中有多少是來自cyclo銷售多出3,000萬美元?另外,第四季指引看起來大約下滑150個基點,你能否再拆解得更細一點?因為看起來cyclo只下降500萬美元,所以我想更了解第三季到第四季之間的變化動態。

  • - CFO

    - CFO

  • Sure. Just one clarifying comment before I address the rest of the question, cyclo is actually down from Q3 to Q4 sequentially $30 million. So in Q3 we achieved roughly $80 million, we expect to achieve roughly $50 million in Q4.

    當然。在我回答其餘問題前先澄清一點:cyclo其實從第三季到第四季按季是下降3,000萬美元。第三季我們達成約8,000萬美元,第四季我們預期約5,000萬美元。

  • - Analyst

    - Analyst

  • Got it.

    了解。

  • - CFO

    - CFO

  • As it relates to the operating margin of 11% in the quarter, there were really two drivers of that. One relates to the cyclo overperformance and that was about a point and the second relates to the timing of the spending savings that we were able to initiate and that was another roughly 1 point of margin. So if you adjust for those two items, those were the two drivers of the overperformance.

    就本季11%的營業利益率而言,主要有兩個驅動因素。第一是cyclo表現超出預期,約貢獻1個百分點;第二是我們能夠啟動支出節省措施的時點,約再貢獻1個百分點的利益率。因此,若把這兩項調整掉,這兩項就是超預期表現的主要來源。

  • Now, turning sequentially from Q3 to Q4, we're guiding to 9.5% to 10%. And so relative to the 11.2% that we experienced in Q3, there are a number of drivers. First, we have about 1 point of cyclo deterioration from Q3 to Q4. Second, we have about 1 point of foreign exchange deterioration from Q3 to Q4. The other comment is in Q3 we had a large order of ProtoPAM. While that's not necessarily a one-timer, it is a periodic order that we receive and we don't forecast one for Q44. And that's roughly 0.7 points of margin that we're going to lose from Q3 to Q4 that we expected and planned for.

    接著看第三季到第四季的按季變化,我們指引為9.5%到10%。相較於第三季的11.2%,有幾個因素。第一,cyclo從第三季到第四季惡化約1個百分點。第二,匯率從第三季到第四季惡化約1個百分點。另外,第三季我們有一筆較大的ProtoPAM訂單。雖然這不一定是一次性,但它是我們會定期收到的訂單,而我們在第四季預測中沒有納入一筆。這大約是我們從第三季到第四季會少掉的0.7個百分點利益率,這是我們已預期並納入規劃的。

  • But as we think about our performance moving forward, there are two drivers that we're going to continue to experience benefits from, general operational improvements of about 80 basis points and OpEx savings will also continue to accelerate as well. So as we think about it that's what drives the 11.2% to roughly 9.5% to 10%.

    但當我們思考未來的表現時,有兩個驅動因素我們將持續受益:一般營運改善約80個基點,以及營業費用(OpEx)節省也會持續加速。所以綜合來看,這就是從11.2%到約9.5%至10%的原因。

  • - Analyst

    - Analyst

  • Great, Jay. That's very clear. Thank you. And then one big-picture question regarding the request last night from a couple senators for the FTC to investigate saline business broadly among the big three competitors there. I'm sure there's probably not much you can say about that, but I wanted to make sure I had a good understanding.

    很好,Jay。這非常清楚。謝謝。另外一個較宏觀的問題:昨晚有幾位參議員要求FTC調查生理食鹽水(saline)業務,涵蓋那裡三大競爭者。我想你們可能不方便多說,但我想確認我理解正確。

  • In the current LRP, this business is a decent chunk of the overall whole. I mean, I assume you've been assuming pretty decent price increases in that business in your LRP. Could you just confirm what kind of price increases you've got assumed in the LRP for saline going forward?

    在目前的長期計畫(LRP)中,這項業務在整體中占有相當比重。我的意思是,我假設你們在LRP中對該業務已假設相當不錯的價格上漲。你能否確認一下,你們在LRP中對未來生理食鹽水的價格上漲,假設的是什麼樣的幅度?

  • - CFO

    - CFO

  • Overall in the low-range plan, we had fairly modest price increases across the portfolio in some product categories. We had low increases in other product categories, we actually had price declines. Bob, do you want to add anything?

    整體而言,在長期計畫中,我們對投資組合中某些產品類別假設的價格上漲相當溫和。在其他產品類別,我們假設的漲幅較低,甚至我們其實假設價格下滑。Bob,你要補充什麼嗎?

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks for asking the question, Bob. And, again, I'm somewhat limited in terms of what we can say, but maybe some thoughts I would share. I think everybody appreciates the fact that IV solutions are probably one of the best medical values in healthcare today. We've used the analogy of the cost of an IV as less than a cup of coffee or a bottle of water that you'd buy at 7-Eleven, right?

    謝謝你提出這個問題,Bob。同樣地,我們能說的內容有些限制,但我可以分享一些想法。我想大家都認同,IV輸液(IV solutions)可能是當今醫療保健中最具價值的醫療項目之一。我們曾用過一個比喻:一袋IV的成本,比你在7-Eleven買的一杯咖啡或一瓶水還便宜,對吧?

  • I will tell you all, we've made extraordinary efforts to maximize the availability of products to address the shortage, including significant investments to identify and secure additional sources of supply. By the way, this includes working with the FDA to get one of our foreign plants in Spain approved to import product from Spain to help mitigate the shortage situation. We continue to work with them on other international sourcing locations as well.

    我可以告訴各位,我們已做出非常大的努力來最大化產品供應,以因應短缺,包括投入大量資本來辨識並確保額外的供應來源。順帶一提,這也包括與FDA合作,讓我們位於西班牙的一座海外工廠取得核准,能從西班牙進口產品,以協助緩解短缺情況。我們也持續就其他國際採購來源地與他們合作。

  • The average price for IVs has increased at a fairly modest level over the past, and Jay commented on our views going forward. So I would just conclude say we're confident in our practices. I would characterize them as reasonable, appropriate. But, again, just to reiterate, we're taking every step we possibly can to make product available to arrest the shortage.

    過去一段時間,IV的平均價格上升幅度相當溫和,而Jay也已談到我們對未來的看法。所以我最後想說的是,我們對自身作法有信心。我會形容這些作法是合理且適當的。但再次重申,我們正在採取一切可能的措施,讓產品能夠供應市場,以遏止短缺。

  • So beyond that, I won't expand any further, Bob. But thanks for asking the question.

    所以除此之外,我就不再多做延伸了,Bob。不過謝謝你提出這個問題。

  • - Analyst

    - Analyst

  • Great. Thanks for taking the questions.

    很好。謝謝你回答問題。

  • - CFO

    - CFO

  • Sure.

    當然。

  • Operator

    Operator

  • Our next question comes from David Lewis with Morgan Stanley. Your line is open.

    下一個問題來自摩根士丹利(Morgan Stanley)的 David Lewis。您的線路已開通。

  • - Analyst

    - Analyst

  • Good morning. Bob, just to start with you really quickly here, emerging market commentary across the coverage universe this quarter has varied amongst companies. I think you commented your [EM] business was generally in line with what you talked about back in May.

    早安。Bob,我先很快從你這邊開始。這一季在我們覆蓋的公司範圍內,對新興市場的評論各家公司不一。我記得你提到你們的[EM]業務大致符合你們在 5 月時談到的情況。

  • Can you talk about how you saw in the business in May, what you are seeing here in the third and early fourth quarter, and how you describe your EM business here from a gross perspective. Is it stable, is it slowing, is it accelerating?

    你能談談你們在 5 月時看到的業務狀況、你們在第三季以及第四季初看到的情況,以及從總體(gross)的角度你會如何描述你們的新興市場業務嗎?它是穩定、放緩,還是在加速?

  • - CEO and Chairman

    - CEO and Chairman

  • Yes. So thanks for asking the question, David. Yes, I characterize it as generally in line. Frankly, it's a tad softer than what we had messaged in May, although it's hanging in there pretty well and probably stronger than a lot of other companies. And I think that speaks to, as I mentioned in my prepared comments, the, quote, unquote, essential nature of our products and so on.

    是的。David,謝謝你提這個問題。是的,我會把它描述為大致符合。坦白說,它比我們 5 月傳達的訊息稍微疲軟一些,但仍然撐得不錯,而且可能比很多其他公司都要強。我想這也呼應了我在事先準備的發言中提到的——我們產品的「必需性」(quote, unquote)等等。

  • But, look, the reality is, and we all know what's going on, emerging markets are a real challenge right now. And I'm not going to project a significant turnaround in the near term, but I do think the guidance that we provided over our LRP in terms of revenue growth will be achieved over the five-year period of time. I would tell you that one business that has been particularly hit by that has been kind of the traditional in-center hemodialysis business which we saw a disproportionate impact of the softening of the emerging markets.

    不過,現實是——而且我們都知道正在發生什麼——新興市場目前確實是一大挑戰。我不會預期短期內會有顯著反轉,但我確實認為,我們在 LRP 中就營收成長所提供的指引,會在五年期間內達成。我會告訴你,受到這個影響特別明顯的一塊業務,是較傳統的院內(in-center)血液透析業務;我們看到新興市場轉弱對它造成了不成比例的影響。

  • But just so you don't misinterpret my comments, emerging markets, continued investment in emerging markets, given the nature of our products, will continue to be an important aspect of our growth prospects over the LRP.

    但為了避免你誤解我的意思:鑑於我們產品的特性,新興市場以及對新興市場的持續投資,仍將是我們在 LRP 期間成長前景的重要面向。

  • - Analyst

    - Analyst

  • Maybe just two quick ones. Bob, just one more strategic for you. You mentioned you were transformative in your M&A commentary. Is transformative M&A possible during the CEO transition? And then second one just for Jay, in Fluid Systems there's a lot of strength there. Was that systems or disposables mix, what was the bigger driver? And specifically can you flush out what was it about the disposable mix that drove the acceleration? Thank you.

    也許再兩個簡短的問題。Bob,再問你一個策略面的問題。你在併購(M&A)的評論中提到「具變革性」。在 CEO 交接期間,有可能進行具變革性的併購嗎?第二個問題給 Jay:在 Fluid Systems 方面表現很強。這是系統(systems)或耗材(disposables)的組合(mix)所致?哪一個是更大的驅動因素?另外,能否具體說明是耗材組合的哪些因素帶動了加速?謝謝。

  • - CEO and Chairman

    - CEO and Chairman

  • I would say in the first part, transformative is a relative term, but, obviously, we're open-minded to things that are material. I will tell you that I [kept] dialogue with our board on some things that we might want to consider doing, relative to the timing of this as it relates to succession. I guess we needed to find the succession timing first and then go from there.

    第一部分我會說,「具變革性」是相對的概念,但很顯然,我們對於具一定規模(material)的機會保持開放態度。我可以告訴你,我一直就一些我們可能想要考慮的事項,與董事會保持對話,並且會把時點與接班(succession)安排連結起來考量。我想我們得先確定接班的時點,然後再往下推進。

  • But the succession has not gotten in the way of us having strategic dialogue with our Board in this regard, and I'm confident that, based on the timing of the succession, that that dialogue will continue, David, okay? Jay, do you want to add something?

    但接班並沒有妨礙我們就此與董事會進行策略性對話;我也有信心,基於接班的時程安排,這樣的對話會持續下去,David,好嗎?Jay,你要補充嗎?

  • - CFO

    - CFO

  • Sure. And as it relates to the Infusion Systems strength, really, the key driver of that was the sale of the SIGMA Spectrum pump in the US. We did see mid to high single digit sales growth of access, but from an overall driver standpoint, we're pleased with the progress we're making on the Infusion pump launch, that's going very well, and that was the key driver in the quarter that led to the double-digit growth.

    當然。至於輸注系統(Infusion Systems)的強勁表現,主要驅動因素其實是 SIGMA Spectrum 幫浦在美國的銷售。我們也看到通路(access)有中到高個位數的銷售成長,但就整體驅動因素而言,我們對輸注幫浦上市推進的進展感到滿意,進展非常順利;這是本季帶動雙位數成長的關鍵因素。

  • - Analyst

    - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • Operator

    Operator

  • Our next question come from Mike Weinstein with JPMorgan, your line is open.

    下一個問題來自摩根大通(JPMorgan)的 Mike Weinstein,您的線路已開通。

  • - Analyst

    - Analyst

  • Thank you. I just want to go maybe back the first couple questions on the call. So just to flush out the quarter, Jay, if you broke it down, the different upside drivers in the quarter between cyclo delay, the gains and [that's and other] that were in the other income line, the ProtoCAM shipment this quarter, and then maybe the continuing ops, how would you break that down?

    謝謝。我想回到電話會議一開始的前幾個問題。為了更清楚拆解本季表現,Jay,如果你把本季不同的超預期(upside)驅動因素拆開來看——包括 cyclo 延遲、其他收益(other income)科目中的收益與[that's and other]、本季 ProtoCAM 出貨,以及可能還有持續營運(continuing ops)——你會如何拆解?

  • - CFO

    - CFO

  • Sure. The ProtoCAM piece was actually included in our original guidance, so that was not an upside to the guidance, but that was about $0.025 roughly of EPS that we had expected. The important thing about ProtoPAM is, like I said in my comments earlier, it is not a one-time order. These are periodic orders that we received, we just don't receive them every quarter, so it was an expected driver of performance in the quarter.

    當然。ProtoCAM 的部分其實已包含在我們原先的指引中,所以它不是超出指引的上行因素;我們原本預期它對 EPS 的貢獻大約是 0.025 美元。ProtoPAM 的重點在於——就像我先前評論所說——它不是一次性訂單。這些是我們會收到的週期性訂單,只是並非每一季都會收到,因此它是本季表現中一個預期內的驅動因素。

  • Relative to our $0.30 midpoint, as you said, there were three upsides. One relates to cyclophosphamide. We had about roughly $30 million of unplanned upside in that category. One relates to other income. We had forecasted certain other income for the second half of the year, but we did over achieve that largely driven by balance sheet positions that we had in place in overseas entities driving foreign exchange gains and that was about $0.03 of over achievement.

    相對於我們 0.30 美元的中點,如你所說,有三個上行因素。其中一個與 cyclophosphamide(環磷醯胺)有關。我們在該類別有大約 3,000 萬美元的非預期上行。另一個與其他收益(other income)有關。我們原本預測下半年會有一定的其他收益,但我們實際上超額達成,主要是因為我們在海外實體的資產負債表部位帶來外匯收益;這部分的超額達成約為 0.03 美元。

  • And then, finally, the OpEx savings that I described earlier was about $25 million, between $0.03 and $0.04 of impact in the quarter. And as I said, that was a very important component for us to put in place early on this margin-improvement journey.

    最後,我先前提到的營運費用(OpEx)節省約 2,500 萬美元,對本季影響約在 0.03 到 0.04 美元之間。如我所說,這是我們在這段改善利潤率旅程中,早期就必須到位的一個非常重要的組成部分。

  • - Analyst

    - Analyst

  • So you would characterize it is as $0.03 to $0.04 as what you would view as being ongoing?

    所以你會把其中 0.03 到 0.04 美元,視為你認為屬於可持續(ongoing)的部分?

  • - CFO

    - CFO

  • Yes, exactly. That would be more ongoing.

    是的,完全正確。那部分會更偏向持續性。

  • - Analyst

    - Analyst

  • Okay. Perfect. And then just to make sure we're thinking about the Baxalta stake correctly, Jay, is your priority still, besides the pension the revolver that comes due in December?

    好的。非常好。接著,為了確認我們對 Baxalta 持股的理解正確,Jay,你的優先順序仍然是——除了退休金之外——12 月到期的循環信貸(revolver)嗎?

  • - CFO

    - CFO

  • Yes. Maybe just taking a step back -- thanks for the question, Mike. I'll make some further comments on the retained stakes so everyone is on the same page. The strategy with the retained stake remains the same. Our objective is to maximize the after-tax value. We have a private-letter ruling from the IRS which supports essentially three mechanisms for us to utilize that stake over the next 18 months in order for us to achieve that tax-free status that I described.

    是的。也許先退一步說——謝謝你的問題,Mike。我會就保留持股(retained stakes)再補充一些說明,讓大家理解一致。保留持股的策略維持不變。我們的目標是將稅後價值最大化。我們已取得 IRS 的私人裁定(private-letter ruling),基本上支持我們在未來 18 個月內運用該持股的三種機制,以達成我所描述的免稅(tax-free)狀態。

  • One is an equity-for-equity exchange,\; one is an equity-for-debt exchange; and one is contribution to our pension plan. As it relates to progress that we're making in the quarter, we are continuing our discussions on the pension with the Department of Labor and we're very confident that we'll receive the appropriate approvals that will allow us to make a pension contribution and we were pleased with the progress in the quarter.

    其一是以股換股(equity-for-equity exchange)\; 其二是以股換債(equity-for-debt exchange);其三是提撥至我們的退休金計畫。就本季的進展而言,我們持續與勞工部(Department of Labor)就退休金議題進行討論,我們非常有信心能取得適當核准,使我們得以進行退休金提撥;我們也對本季的進展感到滿意。

  • As it relates to equity for debt, you're right, we did -- Baxalta, on our behalf, filed an S-1 in the quarter which we have earmarked for a piece of debt that expires in December. The reason I like that debt is because it's a very low-cost way for us to use the retained stake in the sense that there are no premium or breakage fees associated with retiring that piece of debt. So it really does help achieve our objective.

    就以以股換債而言,你說得沒錯,我們確實——Baxalta 代表我們在本季提交了一份 S-1,我們已將其預留用於一筆將於 12 月到期的債務。我之所以喜歡那筆債務,是因為對我們而言,利用保留持股來處理它是一種成本非常低的方式,因為提前清償那筆債務不會產生任何溢價或解約費用。因此,這確實有助於達成我們的目標。

  • To the extent that the market conditions are ripe and we feel like we have a transaction window that's appropriate for us to take advantage of, we do expect to target that piece of debt with a portion of the Baxalta equity stake. More broadly, we will think about equity for debt and looking at the overall bond complex in the form of a secondary offer and with a modified debt tender later on. So overall that all continues as we expect moving forward, and we do -- we'll evaluate conditions as we move forward to see if there is an opportunity for us to target that piece of debt prior to December.

    在市場條件成熟、且我們認為有合適的交易窗口可供把握的情況下,我們確實預期會以 Baxalta 的部分股權持股來鎖定那筆債務。更廣泛地說,我們會考慮以股換債,並以二次發行的形式檢視整體債券組合,之後也可能進行經調整的債務要約收購。因此,整體而言,這些都會如我們預期般持續推進;同時——我們也會在往前推進的過程中評估條件,看看是否有機會在 12 月之前鎖定那筆債務。

  • - Analyst

    - Analyst

  • That's very helpful. Thanks, Jay; thanks, Bob.

    這非常有幫助。謝謝你,Jay;謝謝你,Bob。

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks, Mike.

    謝謝你,Mike。

  • Operator

    Operator

  • Our next question comes from Matt [Miksic] with UBS. Your line is open.

    下一個問題來自 UBS 的 Matt [Miksic]。請開線。

  • - Analyst

    - Analyst

  • Thanks. Thanks for taking my question. So one followup for Bob on your questions about M&A and strategic investment, not to beat a dead horse, but I did just want to touch on one aspect of your meeting in May. It was talking about accelerating profitable growth, and so we think of assets or transformative or mid-sized acquisitions and so on. Should we be thinking about something that is a synergy play on your platform and with cost synergies involved or should we be thinking of something that is, in fact, going to help sort of drive growth here as well?

    謝謝。謝謝讓我提問。我想就你們關於併購與策略性投資的問題,對 Bob 再追問一點;不是要老調重彈,但我確實想觸及你們 5 月會議中的一個面向。當時談到要加速獲利性成長,因此我們會想到資產收購、具轉型意義或中型規模的併購等等。我們應該把它理解為在你們平台上做協同、並包含成本協同效益的交易?還是應該理解為其實也會有助於推動這裡的成長?

  • - CEO and Chairman

    - CEO and Chairman

  • Matt, I'm not sure I can expand a lot beyond what I said in answer to one of the earlier questions on this, but maybe to reiterate a point the priority would be things that, as I said before, [flush] out our acute care hospital channel. So that's another way of saying commercial synergy where one plus one is greater than two, clearly structural costs would be part of it as well, and targets we would look at would be meaningfully accretive, but it would be both a commercial synergy play, leveraging the acute care channel, and depending upon what the target may be, structural costs as well.

    Matt,我不確定我能在先前回答其中一個早前問題時所說的內容之外再擴充太多;但或許重申一點:優先事項會是我之前提到的——把我們的急性照護醫院通路「補齊」。換句話說,就是商業協同效益(1+1 大於 2);當然,結構性成本也會是其中一部分。我們會看的標的也會是具有顯著增益(accretive)的;但會同時是商業協同的布局、利用急性照護通路,並且視標的而定,也會包含結構性成本的部分。

  • - Analyst

    - Analyst

  • And one, if I could, follow up on a question earlier on pumps, if you could talk a little bit about the success you've had there. That process is, of course, winning contracts, placing channels and enjoying and driving the pull-through of utilization. Could you talk a little bit about maybe where you wanted this year -- if there is a point where you've either hit changing comps or change in mix or just some color on the process of that rollout. And then I have one more followup for Jay.

    另外,如果可以的話,我想追問先前關於幫浦的問題,請你談談你們在那方面取得的成功。那個流程當然包括贏得合約、鋪設通路,以及享受並推動使用量的拉動效應(pull-through)。你能否談談今年你們原本希望達到的位置——是否已經出現比較基期變化、產品組合變化,或是就推廣(rollout)流程提供一些補充說明?然後我還有一個要追問 Jay 的問題。

  • - CEO and Chairman

    - CEO and Chairman

  • Yes. So the momentum on the SIGMA launch, as I commented, is building. We're very pleased with the market response to date. Just to ground everyone, you'll recall in our Investor Conference and the LRP projections we assumed that we would regain approximately 5 of 10 share points in the US lost over the last number of years because of the colleague challenges and so on.

    好的。如我所評論的,SIGMA 上市的動能正在累積。我們對目前市場的反應非常滿意。先讓大家有個基準:你們會記得,在我們的投資人會議以及 LRP(長期規劃)預測中,我們假設能收復過去幾年因同業挑戰等因素在美國流失的 10 個市占點中的約 5 個。

  • All I would say, Matt, on that is given the early impact of the relaunch, we are highly confident that we will be able to regain at least those 5 share points in the LRP. And I think our longer-term aspiration of recovering all of that share loss, if not more, is certainly very viable. Admittedly there's a little bit of pentup demand, and so we want to continue to gauge that and monitor the sustainability of that. But, again, all I can just really say qualitatively or subjectively, is we're very, very pleased with the market response to Spectrum. The product's performing very well and really, beyond that, I'm not going to expand. Hopefully that helps.

    Matt,我對此想說的是:鑑於這次重新上市的早期影響,我們非常有信心至少能收復 LRP 中所假設的那 5 個市占點。而且我認為,我們更長期的願景——把那些流失的市占全部收回、甚至更多——絕對是非常可行的。坦白說,確實存在一些被壓抑的需求,因此我們會持續衡量並監控其可持續性。但再次強調,我能提供的主要是定性或主觀的觀察:我們對市場對 Spectrum 的反應非常、非常滿意。產品表現非常好;除此之外,我就不再延伸了。希望這有幫助。

  • - Analyst

    - Analyst

  • Sure. Well, congrats on the progress so far. Jay, comment -- you mentioned a couple times the gains, FX gains as being one of the positives. I was wondering if you could highlight -- those sounded like balance sheet or asset-related gains below the operating line.

    了解。那麼,恭喜目前為止的進展。Jay,你提到幾次外匯收益(FX gains)是其中一個正面因素。我想請你說明一下——聽起來那些像是營業利益線以下、與資產負債表或資產相關的收益。

  • Could you talk a little bit about the impact of the sort of FX gains that dropped through the P&L in terms of the offsets, either natural edges or otherwise, if you have a net, a feel for what the impact of FX was to the P&L?

    你能否談談這類計入損益表(P&L)的外匯收益之影響,以及其抵銷項(不論是自然避險或其他方式)?如果你有淨額的概念,外匯對 P&L 的影響大概是多少?

  • - CFO

    - CFO

  • Sure. So to your point, the gains that I was pointing to are really other income-related gains related to balance sheet positions held in overseas entities that are mark to market as part of our standard process on a monthly and quarterly basis. As it relates to overall impact of FX, I did mention that sequentially from Q3 to Q4, excluding the area of sundry, we are seeing some deterioration in foreign exchange. So sequentially from Q3 to Q4, we have about $0.04 of impact that we expect to see and that's about $0.01 to $0.02 worse than our expectations driven by deterioration in the number in currencies. We've seen a lot of volatility in emerging markets in particular.

    當然。如你所說,我所指的收益主要是其他收益(other income)相關的收益,來自海外實體所持有的資產負債表部位;依我們標準流程,每月與每季都會按市價評價(mark to market)。至於外匯的整體影響,我確實提到過,從 Q3 到 Q4 的序列變化來看,若排除雜項(sundry)部分,我們看到外匯有些惡化。因此,從 Q3 到 Q4,我們預期會看到約 0.04 美元的影響;而這比我們原先預期還差約 0.01 到 0.02 美元,主要是因為多種貨幣的數字惡化所致。我們特別看到新興市場出現很大的波動。

  • From a hedging standpoint overall, for the developed market currencies, we do have an approach where we look to hedge a portion of our exposure with the use of options. And then for those currencies that we don't there are a lot of emerging market currencies today that we don't actually hedge in because it's not economic to do so. In the case of those markets, there are some natural hedges that we have in place.

    就整體避險而言,對於已開發市場貨幣,我們採取的做法是使用選擇權來避險一部分曝險。至於我們沒有避險的那些貨幣——目前有很多新興市場貨幣我們其實不做避險,因為從成本效益上不划算。在那些市場,我們有一些自然避險機制。

  • As you know, we have manufacturing facilities in 40 countries around the world, in 40 manufacturing facilities in 25 countries around the world. So as a result of that, we do have some natural expense offsets to the sales that we have in place and that we don't have that many products that are truly global in nature creating additional foreign exchange exposures. So we will continue to be exposed to foreign exchange, it's an area we watch very closely. We do see this $0.01 to $0.02 impact, but there are active hedging programs we have in place. There are some balance sheet programs we have in place and then there are also the natural hedges that I just mentioned.

    如你所知,我們在全球 40 個製造據點、分布於 25 個國家。因此,我們確實有一些自然的費用抵銷,可用來對沖我們的銷售;而且我們真正屬於全球化的產品並不多,不至於造成額外的外匯曝險。所以我們仍會持續暴露於外匯風險之下,這是我們非常密切關注的領域。我們確實看到這 0.01 到 0.02 美元的影響,但我們也有積極的避險計畫在進行。我們也有一些資產負債表層面的計畫,另外還有我剛提到的自然避險。

  • - Analyst

    - Analyst

  • Great. Thanks so much.

    很好。非常感謝。

  • Operator

    Operator

  • Our next question comes from Larry Keusch with Raymond James. Your line is open.

    下一個問題來自 Raymond James 的 Larry Keusch。請開線。

  • - Analyst

    - Analyst

  • Okay, thanks. Good morning, everyone.

    好的,謝謝。各位早安。

  • - CEO and Chairman

    - CEO and Chairman

  • Hi, Larry.

    嗨,Larry。

  • - Analyst

    - Analyst

  • Bob, I was wondering if you might take a stab at just giving us some thoughts around the environment in the US and Europe? I know you already talked through emerging markets, but how about in some of the other geographies?

    Bob,我想請你試著談談你對美國與歐洲環境的一些看法?我知道你已經談過新興市場了,那其他一些地區呢?

  • - CEO and Chairman

    - CEO and Chairman

  • Ironically, probably the US market is as stable or strong as any geography the world right now. You saw that with our performance in the first half of the year in the US where we're seeing some recovery, we're seeing some expanded expenditure on capital goods which helps our pump business, and we would project that that's going to continue. Europe clearly continues -- developed Europe continues to be a challenge.

    諷刺的是,可能就目前而言,美國市場在全球各地之中算是最穩定或最強勁的之一。你從我們今年上半年在美國的表現就看得出來,我們看到一些復甦,也看到資本財支出有所擴大,這對我們的幫浦業務有幫助,而我們預期這種趨勢將會持續。歐洲顯然仍然——已開發的歐洲仍然是一項挑戰。

  • We don't see any significant improvement there. I don't see any significant deterioration as well going forward. And then emerging markets, I think both Jay and I have commented on this morning, it's really kind of an unknown in the near term, although clearly long term, all of these countries are increasing the amount of spend to healthcare and that particularly plays to our strength in terms of the essential nature of our products.

    我們看不到那裡有任何顯著改善。同時我也不認為未來會有任何顯著惡化。至於新興市場,我想 Jay 和我今天早上都提過,短期內確實有點未知數;不過很明顯地,長期而言,這些國家都在增加醫療保健支出,而這特別符合我們的優勢,因為我們的產品具有不可或缺的本質。

  • So beyond that, I realize that's all very qualitative. I don't know if there's anything, Larry, specifically within that you'd like me to comment on?

    所以除此之外,我知道這些都相當偏質性。Larry,不知道在這裡面是否有任何你希望我特別評論的部分?

  • - Analyst

    - Analyst

  • No. That's helpful. I just had two other questions for you. You did mention in the prepared comments about some competition in dialyzers. I recognize that's not necessarily new, but if you could speak to that and weave in there sort of where we are on the dializer capacity expansion? And then the other quick question for you was if I just do the very high-level math on the operating margin for the second half, it implies somewhere around 10.5% or so. You guys had been focused on 11% for 2016, so how should we think about that 100 basis-point improvement in 2016 from the initially target of 9% in the second half of this year?

    沒有。這很有幫助。我另外還有兩個問題想請教你。你在事先準備的評論中確實提到透析器方面有一些競爭。我知道這不一定是新情況,但如果你能談談這點,並順帶說明一下我們在透析器產能擴張方面目前的進度就更好了。另外一個快速問題是,如果我用非常高層次的方式去算下半年營業利益率,大概暗示在 10.5% 左右。你們原本聚焦在 2016 年達到 11%,那麼我們應該如何看待 2016 年相較於今年下半年最初 9% 目標所隱含的 100 個基點改善?

  • - CEO and Chairman

    - CEO and Chairman

  • Okay. Let me comment on the dializer. Competition may be a little bit more broadly on the Renal performance. And then, Jay, if you would pick up on the second part of the question. So, first of all, just kind of stepping back, we continue to believe the ESRD patient growth globally is growing around 5%.

    好的。我先評論一下透析器。競爭可能更廣泛地反映在腎臟(Renal)業務的表現上。然後,Jay,請你接著回答問題的第二部分。首先,先退一步看,我們仍然相信全球 ESRD(末期腎臟病)患者的成長率大約在 5%。

  • Our performance to date is impacted really by a number of factors. First of all, as I commented in the prepared comments, we've decided to forego some lower-margin tenders which has impacted us, in the short term, we continue to manage through conversion of distributors that Gambro had to go indirect, which is the right thing to do strategically and long term, but in the short term can be somewhat disruptive. And then, of course, I think a more competitive environment in the in-center chronic business than what we had anticipated, although in fairness I would say in our modeling we've always assumed some modest price erosion over the long-range plan for dializers.

    我們迄今的表現其實受到多項因素影響。首先,如同我在事先準備的評論中提到的,我們決定放棄一些低毛利的標案(tenders),短期內因此受到影響;同時,我們仍在管理 Gambro 先前的經銷商轉換,改為間接模式,這在策略與長期而言是正確的作法,但短期可能會有些干擾。此外,當然還有一點:院內(in-center)慢性透析業務的競爭環境比我們原先預期更激烈;不過公平地說,在我們的模型中,對於透析器在長期計畫期間出現一些溫和的價格侵蝕,我們一直都有所假設。

  • In terms of expanded capacity, that won't come on until late 2016 in our investment in Opelika, Alabama. We also, as I think you know, are expanding capacity in the production of PD solutions in China and Southeast Asia and so on. So the combination of the capacity expansion as well as an array of new product launches. AMIA, I talked about the approval in the US, which is very exciting. That really builds on a home choice, which is a $1.5 billion system globally today, so that's big. PrixMAX, the CLARIA launch in Europe and then, of course, VIVIA for home HD.

    就產能擴張而言,我們在阿拉巴馬州 Opelika 的投資要到 2016 年底才會投產。另外,如你所知,我們也在中國與東南亞等地擴增腹膜透析(PD)溶液的產能等等。因此,產能擴張加上多項新產品上市的組合。AMIA,我提到在美國獲准,這非常令人振奮。這實際上是建立在居家治療選擇之上,而這在全球目前是一個 15 億美元的系統,所以規模很大。還有 PrixMAX、在歐洲推出的 CLARIA,以及當然還有用於居家血液透析(home HD)的 VIVIA。

  • So whether it's capacity expansion or new product flow, that's what's going to accelerate the Renal growth going forward. I'm confident that as we move into 2016 we're going to ramp up the year-to-year growth in the Renal business. But the reality is that the product in-center business, particularly in dializers continues to be very competitive. We anticipated that -- that perhaps to a great degree than we had anticipated, but we're looking forward to the capacity expansion, so that's about as much color as I can provide there. Jay, you want to handle the other?

    所以不論是產能擴張或新產品導入,這些都將在未來加速腎臟業務的成長。我有信心,當我們進入 2016 年時,腎臟業務的年對年成長將會加速。但現實是,院內產品業務,特別是透析器,仍然競爭非常激烈。我們確實預期到——但可能比我們原先預期的程度更高;不過我們期待產能擴張帶來的助益,所以我能提供的大概就這些背景。Jay,你要回答另一個問題嗎?

  • - CFO

    - CFO

  • Sure. On the operating margin, we did guide to 9% for the second half and we're pleased the second half is running better than that. As it relates to 2016, we actually guided to a 10% margin for 2016 and 11% in 2017, essentially 100 basis points of margin improvement per year. It's important to note that in 2016 we also expected about 100% of -- 100 basis points of deterioration due to cyclo. So, in fact, the organic or the true growth in margin in 2016 was really 200 basis points.

    當然。關於營業利益率,我們確實指引下半年為 9%,而我們很高興下半年的表現優於此水準。至於 2016 年,我們其實指引 2016 年為 10% 的利益率、2017 年為 11%,基本上每年提升 100 個基點的利益率。需要注意的是,2016 年我們也預期會因 cyclo 造成約 100 個基點的惡化。因此,事實上 2016 年的有機、或真正的利益率成長其實是 200 個基點。

  • But, like I said, our guidance for 2016 was 10%. Based on our performance in the second half thus far, we're pleased and we have confidence in our ability to achieve the projections that we've shared. At this stage, we're not making any changes to guidance moving forward. There's a lot of moving pieces, things like foreign exchange, pension, operational improvements, et cetera, and we're actually going through a budgeting process as we speak to firm up our 2016 expectations. You can expect to hear an update from us on our January earnings call.

    但如我所說,我們對 2016 年的指引是 10%。基於我們目前下半年的表現,我們感到滿意,也對達成我們已分享的預測有信心。在這個階段,我們不會對未來的指引做任何調整。因為有很多變動因素,例如匯率、退休金、營運改善等等,而我們也正在進行預算編製流程,以敲定我們對 2016 年的預期。你可以期待在我們一月的財報電話會議上聽到更新。

  • - Analyst

    - Analyst

  • Okay. Great. Thank you.

    好的。很好。謝謝你。

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks, Larry.

    謝謝你,Larry。

  • Operator

    Operator

  • In the interest of time, we'll take two more questions. Our next question comes from Rick Wise with Stifel. Your line is open.

    為了時間起見,我們再接受兩個問題。下一個問題來自 Stifel 的 Rick Wise。你的線路已開通。

  • - Analyst

    - Analyst

  • Good morning. Hi, Bob. I want to follow up on the question on operating margins, if I could, and maybe push you a little further. Just when companies, I've noticed over the years, start down this path of focusing more intently on cost reduction and efficiency, sometimes they can even surprise themselves. Maybe -- a couple things, for example, the global work force reduction. How quickly will that $130 million savings hit the P&L?

    早安。嗨,Bob。如果可以的話,我想追問一下關於營業利益率的問題,並且可能再請你多談一點。我注意到多年來,當公司開始走上更專注於成本削減與效率提升的路徑時,有時甚至會讓自己都感到意外。例如幾件事:像是全球人力縮減。那 1.3 億美元的節省會多快反映到損益表(P&L)上?

  • And maybe, Jay, talk to us about the possibility of other discretionary spending cuts. I mean, just remind us what some of the opportunities are. Is it in supply chain, is it back office, is it IT, just help us understand the larger directional picture if you would.

    另外,Jay,也請你談談是否還有其他可裁減的自由裁量支出。我的意思是,請再提醒我們有哪些機會。是在供應鏈、後勤支援(back office)、IT,還是其他方面?如果可以的話,請幫助我們理解更大的方向性全貌。

  • - CEO and Chairman

    - CEO and Chairman

  • So let me maybe comment, Rick -- this is Bob -- on kind of set this up a little bit with some specifics and then Jay can pick up the second part of your question. First of all, in terms of timing, the actions that we discussed this morning are going to largely be completed by the end of this year, so this is pretty immediate.

    那我先評論一下,Rick——我是 Bob——先用一些具體內容把背景鋪陳一下,然後 Jay 再接著回答你問題的第二部分。首先,就時程而言,我們今天早上討論的行動大多會在今年年底前完成,所以這是相當即時的。

  • As you gathered from our prepared comments, this is the first part of what will be other actions that we will take over time. One thing we have to continue to be sensitive to, as Jay commented earlier, is the organizational support requirements for the Baxalta spinoff and so on, so we want to be cognizant of that as well. But we do think there are meaningful actions going forward. And, of course, what we didn't comment on was the completion of the Gambro integration which continues on track as well.

    如你從我們事先準備的評論中所理解的,這只是我們未來一段時間內將採取的其他行動的第一部分。我們必須持續留意的一點是,如同 Jay 先前提到的,Baxalta 分拆(spinoff)等事項對組織支援的需求,因此我們也要對此保持敏感與審慎。但我們確實認為未來還有具實質意義的行動可以推進。當然,我們沒有特別評論的是,Gambro 整合的完成也仍按計畫進行。

  • So in aggregate, fairly meaningful undertakings, the impact of which will be near term -- maybe to give you some specifics on the reduction which we characterized as about 5% of non-manufacturing jobs. This translates into about 1,400 jobs globally, about 70% are existing head count, about one-third of which are cancellation of [open] positions. Roughly two-thirds of the reductions are outside the United States and really spread around the world fairly evenly. So hopefully that's helpful.

    因此,整體而言,這些都是相當有意義的舉措,其影響將在短期內顯現——也許給您一些具體數字,關於我們所描述約占非製造職位 5% 的削減。這相當於全球約 1,400 個職位,其中約 70% 為現有編制,約三分之一則是取消[空缺]職位。約三分之二的削減發生在美國以外,且在全球各地相當平均地分布。希望這些資訊對您有幫助。

  • Jay, you want to pick up on the second part of the question?

    Jay,你要接著回答問題的第二部分嗎?

  • - CFO

    - CFO

  • Yes. Just to elaborate (technical difficulty). Overall we commented at our Investor Conference outlining 430 basis points of very specific cost improvements, 90 of which comes from Gambro, 80 of which comes from manufacturing, 50 of which comes from the pension, and 210 basis points related to G&A. And so by no means were we surprised by the size, scope or scale of the restructuring that we announced.

    是的。我再補充說明一下(技術問題)。整體而言,我們在投資人會議上提到,概述了 430 個基點、非常具體的成本改善,其中 90 個基點來自 Gambro,80 個基點來自製造,50 個基點來自退休金,另有 210 個基點與一般及行政(G&A)相關。因此,我們對於所宣布重整的規模、範圍或幅度絕非感到意外。

  • And so far everything is moving forward very much in line with our expectations from a cost standpoint. One of the areas to your point that we're very focused on relates to discretionary spending. And we believe there is some opportunity to look hard at certain categories using some zero-based techniques and looking at very detailed spend levels in areas like travel, consulting and some other discretionary spending like marketing and professional services. And so as we go through our budget, that's a clear area of focus for us.

    到目前為止,從成本角度來看,一切進展都非常符合我們的預期。就您提到的重點而言,我們非常關注的一個領域是可自由裁量支出。我們相信,運用一些零基預算(zero-based)的方法,並在差旅、顧問以及其他可自由裁量支出(如行銷與專業服務)等領域檢視非常細緻的支出水準,某些類別仍有機會可以深入檢討。因此,在我們編列預算的過程中,這是我們明確的聚焦領域。

  • We think we have the opportunity pegged appropriately in terms of the impact on our long-range plan financials, but I can assure you, with respect to all of these actions and the overall plan, the three components of the plan that Bob described earlier, we are looking to do better than we've outlined. And we're attempting to do that at each step, and so cost is squarely in that focus, but I wouldn't say we've been surprised by our performance at this stage.

    我們認為,就對長期計畫財務的影響而言,我們已適當地掌握了這個機會,但我可以向您保證,針對所有這些行動以及整體計畫——也就是 Bob 先前描述的計畫三個組成部分——我們希望做到比我們所概述的更好。我們正嘗試在每一步都做到這點,因此成本確實是我們的核心焦點之一,但我不會說在這個階段我們對自身表現感到意外。

  • - Analyst

    - Analyst

  • Great. I'll leave it at that. Thanks for the color. I appreciate it.

    很好。我就先說到這裡。謝謝你提供的補充說明。我很感激。

  • - CEO and Chairman

    - CEO and Chairman

  • Thanks, Rick.

    謝謝你,Rick。

  • Operator

    Operator

  • Our final question comes from Joanne Wuensch with BMO Capital Markets. Your line is open.

    我們最後一個問題來自 BMO Capital Markets 的 Joanne Wuensch。您的線路已開通。

  • - Analyst

    - Analyst

  • Thank you very much for including me and very nice quarter. In Renal, did I understand that you're largely done with the Gambro integration?

    非常感謝讓我提問,也恭喜這一季表現很不錯。在腎臟(Renal)業務方面,我是否理解你們基本上已經完成 Gambro 的整合?

  • - CEO and Chairman

    - CEO and Chairman

  • No. We still have work to do. I think we're approaching the conclusion of it. Jay, you want to comment --

    沒有。我們還有工作要做。我想我們正接近尾聲。Jay,你要不要補充——

  • - CFO

    - CFO

  • Sure.

    當然。

  • - CEO and Chairman

    - CEO and Chairman

  • -- specifically on the dollars (multiple speakers).

    ——特別是就金額而言(多人發言)。

  • - CFO

    - CFO

  • By the end of this year, we expect to have achieved approximately $200 million in savings. And then in 2016 and 2017, we expect $100 million in incremental savings. Really the drivers of the remaining piece relates to certain manufacturing, a consolidation of activity, certain warehousing and distribution consolidation, and then, finally, there are some IT savings. As we roll out Baxter platforms across the Gambro network, there will be some G&A savings and we still have a few IT implementations to go. Those are the primary drivers of the remaining $100 million in savings.

    到今年年底,我們預期將實現約 2 億美元的節省。接著在 2016 年與 2017 年,我們預期還會有 1 億美元的新增節省。剩餘部分的主要驅動因素與某些製造相關、活動整併、部分倉儲與配送整併有關,最後還有一些 IT 節省。隨著我們在 Gambro 網路中推行 Baxter 的平台,將會帶來一些一般及行政(G&A)節省,而且我們還有幾項 IT 導入尚待完成。這些是剩餘 1 億美元節省的主要驅動因素。

  • - Analyst

    - Analyst

  • That's very helpful. As a followup, as we think about 2016, can you remind us where FX may or may not impact different items on the income statement, other than obviously revenue? But how is it going to roll through so that we don't get to 2016 guidance and suddenly have either other income or margins significantly different than expectations?

    這非常有幫助。追問一下,當我們思考 2016 年時,您能否提醒我們,除了顯而易見的營收之外,外匯(FX)可能會或不會如何影響損益表上的不同項目?它會如何逐步反映,讓我們不至於到了 2016 年財測時,突然發現其他收入或利潤率與預期有顯著差異?

  • - CFO

    - CFO

  • Yes, as we look at FX in 2016, what we had assumed in May was essentially a constant FX environment in the sense that we assumed flat currencies over the long-range planned period. To the extent there are departures from that, we'll first look to hedge using various techniques that we've discussed.

    是的,當我們看 2016 年的外匯時,我們在 5 月所採用的假設,基本上是外匯環境維持不變,也就是在長期計畫期間假設各貨幣匯率持平。若實際情況偏離該假設,我們會先運用我們先前討論過的各種方法進行避險。

  • There will be the benefit of natural hedges in place, but as we saw in Q4, based on the change in foreign exchange from Q3 -- from June to today, let's just put it that way, we did see a negative impact of around $0.01 to $0.02 in the fourth quarter.

    我們也會受益於既有的自然避險,但正如我們在第四季所看到的,基於外匯自第三季以來的變動——從 6 月到今天,我們就這麼說——我們確實在第四季看到約 0.01 至 0.02 美元的負面影響。

  • So this will be one of the important assumptions that we update as part of our January guidance, along with many other items that we look forward to discussing with investors.

    因此,這將是我們在 1 月發布財測指引時會更新的重要假設之一,並且還有許多其他項目,我們也期待與投資人進一步討論。

  • - Analyst

    - Analyst

  • Terrific. Thank you so much.

    太好了。非常感謝。

  • Operator

    Operator

  • Thank you, ladies and gentlemen. This concludes today's conference call with Baxter International. Thank you for participating. You may all disconnect.

    謝謝各位女士、先生。今天 Baxter International 的電話會議到此結束。感謝各位參與。各位現在可以掛線。